Knight Therapeutics (GUD.TO) on Thursday said it is launching Wynzora, a topical treatment cream for psoriasis vulgaris in adults and adolescents aged 12 and older, in Canada.
Knight obtained the Canadian rights to Wynzora when it acquired the assets of Paladin Pharma in June last year. The treatment was approved by Health Canada in December.
"The launch of Wynzora in Canada reflects our commitment to continuing to grow our Canadian platform and bring innovative treatment options to patients. Wynzora's unique aqueous cream formulation, enabled by PAD Technology, offers patients and healthcare providers a clinically proven option that combines efficacy with ease of use, an important consideration for a chronic condition that requires long-term management." said Chief Executive Samira Sakhia.
Knight Therapeutic shares were last seen down C$0.15 to C$9.67 on the Toronto Stock Exchange.
Price: $9.67, Change: $-0.15, Percent Change: -1.53%